How changes in the eye’s support matrix change retinal cell metabolism

Metabolic dysfunction from ECM remodeling in diseases of human RPE

NIH-funded research University of Washington · NIH-11136930

The team is testing whether breakdown of the layer under retinal pigment epithelial (RPE) cells forces those cells to make and store extra fat, which may lead to early age-related macular degeneration or related inherited retinal disease.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Washington NIH-funded
Lab location1 site (Seattle, United States)
Project IDNIH-11136930 on NIH RePORTER

What this research studies

From my perspective, the researchers will study human RPE cells and models that carry mutations linked to Sorsby Fundus Dystrophy and features of age-related macular degeneration. They will mimic breakdown of the extracellular matrix (ECM) and track how RPE cells change their usage of branched-chain amino acids and other fuels to make lipids. The lab will use genetic tools such as CRISPR to recreate disease-linked changes and measure lipid buildup, mitochondrial activity, and antioxidant defenses. Findings will be based on experiments with human-derived cells and laboratory models to trace how ECM-derived material alters RPE metabolism.

Who could benefit from this research

Good fit: People with early age-related macular degeneration or with Sorsby Fundus Dystrophy—or those willing to provide donated eye tissue or cells—would be most relevant to this line of research.

Not a fit: Patients with unrelated eye diseases or those with advanced, end-stage vision loss from late AMD are less likely to benefit directly from these metabolic findings in the near term.

Why it matters

Potential benefit: If proven, this work could point to new metabolic targets or treatments to prevent harmful lipid deposits and slow early AMD or related inherited retinal degeneration.

How similar studies have performed: Prior research links ECM changes and TIMP3 mutations to drusen and retinal disease, but the specific idea that ECM breakdown supplies metabolites that reprogram RPE toward branched-chain amino acid-driven lipid synthesis is a newer, not yet proven concept.

Where this research is happening

Seattle, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.